A PYMNTS Company

Novartis Deal May Lead To Cellerys Sale

By  |  June 1, 2021

Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based startup conducting research on a therapy to fight multiple sclerosis (MS), the Swiss drugmaker announced on Tuesday, June 1.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    “Under the agreement, Novartis will support the development of the CLS12311 therapy currently in Phase 2” study, the Basel-based drugmaker said in a statement. “Novartis will have the option to acquire Cellerys upon completion of a Phase 2 trial in the coming years.”

    Cellerys was founded in 2015 as a University of Zurich spin-out by MS researchers. No financial details for the transaction were given by Novartis.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.